---
title: "Descartes-08 in Generalized myasthenia gravis: MG-001 phase 1b/2a"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: MG-001 phase 1b/2a. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 73 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence/mg-001-phase-1b-2a"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: MG-001 phase 1b/2a

<a id="heading-3.1.3"></a>

## 3.1.3 MG-001 Phase 1b/2a

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Primary objective of safety and tolerability; secondary objectives of disease severity and biomarkers

> “The primary objective was to establish safety and tolerability; secondary objectives were to assess MG disease severity and biomarkers.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.1-2"></a>

#### Protocol objectives: safety, tolerability, and manufacturing feasibility

> “The primary objective is to assess the safety, tolerability, and manufacturing feasibility of Descartes-08 in patients with GMG.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Objectives of the phase 1b and phase 2a portions: maximum tolerated dose and dosing schedule

> “The primary objective of the Phase 1b portion of the trial was to determine the maximum tolerated dose of Descartes-08 for patients with MG.”
> “This portion of the trial was designed to assess the safety and preliminary efficacy of Descartes-08 when administered across three different treatment schedules (six doses given twice-weekly, once-weekly, or once-monthly).”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-3.1.3.1-4"></a>

#### Objective of the 12-month follow-up and retreatment report

> “We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).”
> “Here, we report the results of both the final, 12‐month follow‐up analyses and the optional retreatment of participants who met protocol‐specific retreatment criteria.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Eight U.S. sites, recruitment January 2020 to August 2022

> “Eight study sites in the United States recruited subjects between January 7, 2020 and August 3, 2022.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.2-2"></a>

#### Academic centers and community neurology clinics

> “Briefly, this was a multicenter, open‐label, Phase 1/2a study conducted across eight academic centers and community neurology clinics in the United States.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Prospective, open-label, multicenter, nonrandomized phase 1b/2a design

> “MG-001 was a prospective, open-label, multi-center, non-randomised, Phase 1b/2a trial evaluating the safety and clinical activity of Descartes-08 in adult gMG patients requiring immunosuppression.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.3-2"></a>

#### Part 1 intrapatient dose escalation and Part 2 dosing schedules

> “In Part 1, up to three ascending doses of Descartes-08 will be administered to each of 3 to 6 patients; the patients will be staggered at least 21 days apart and will complete a safety review between each dose.”
> “In Part 2, patients will receive up to 6 doses in three different schedules depending on the arm they were enrolled into and will be monitored for up to 1 year to assess the safety and tolerability of a repeated dosing schedule.”

Source: [ClinicalTrials.gov NCT04146051](https://clinicaltrials.gov/study/NCT04146051)

> “Part-2 (n=11) tested 3 dosing schedules at the MTD: twice weekly for 3 weeks (Arm-1), weekly for 6 weeks (Arm-2), and monthly for 6 months (Arm-3).”
> “Enrollment into Part-2 would stop when sufficient data on safety, feasibility, and clinical activity had been gathered to permit the selection of the dosing schedule to be tested in later-stage trials.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.3-3"></a>

#### Assignment to Part 2 arms by investigator discretion and participant preference

> “Participants in Part-2 were assigned to a treatment Arm at investigator’s discretion, taking into consideration each participant’s preferences (predominantly determined by the time burden of each infusion schedule) and enrolment to date.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.3-4"></a>

#### Assessment schedule and safety monitoring committee

> “Participants were evaluated at screening, infusion visits, Weeks 8, 12, 16, and 20, and Months 6, 9, and 12.”
> “Throughout the study, the clinical data were reviewed periodically by a sponsor-funded safety monitoring committee containing experts who have no other relationship with the sponsor or trial conduct.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.3-5"></a>

#### Long-term follow-up schedule of the weekly-dosing arm

> “The group that received Descartes‐08 as six weekly infusions (Arm‐2) had the longest follow‐up, with evaluations at Months 2, 3, 4, 5, 6, 9, and 12 counting from the first infusion, and was therefore included in this analysis.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion criteria: age, MGFA class, autoantibody status, and MG-ADL score

> “Key inclusion criteria were: age ≥18 years; diagnosis of MG (MGFA Disease Class III–IV in Part-1, Class II–IV in Part-2) with presence of an MG-associated autoantibody (anti-acetylcholine receptor [AChR], muscle specific kinase [MuSK], or low-density lipoprotein receptor-related protein 4 [LRP4]).”
> “If seronegative, unequivocal response to cholinesterase inhibitors, and abnormal repetitive nerve stimulation, or increased jitter on single-fiber EMG was required.”
> “Patients had to have MG Activities of Daily Living (MG-ADL) score ≥6 at both screening and baseline; and requiring immunosuppression.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.4-2"></a>

#### Key exclusion criteria

> “Key exclusion criteria were the presence of a major chronic illness that was not well managed; IVIg or plasma exchange within 4 weeks of baseline (first infusion) visit; and the use of non-permitted immune modulators.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.4-3"></a>

#### Stable background immunosuppression required before enrollment

> “All participants had to be on stable doses of prednisone (up to 40 mg) or nonsteroidal immunosuppressants (methotrexate, azathioprine, or mycophenolate mofetil) for 8 weeks prior to enrollment.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.4-4"></a>

#### Protocol exclusions for B-cell depleting agents, calcineurin inhibitors, FcRn antagonists, and complement inhibitors

> “Treatment with rituximab/ocreluzimab or calcineurin inhibitors, e.g., tacrolimus, cyclosporine or cyclophosphamide or Neonatal Fc receptor antagonists, e.g. efgartigimod. Wash-out periods for these agents are 3 weeks before planned leukapheresis and 8 weeks prior to baseline (first infusion) visit.”
> “Patient has started treatment with a Complement 5a (C5a) inhibitor, e.g. eculizumab, within 8 weeks of baseline (first infusion) visit.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="topic-3.1.3.4-5"></a>

#### Protocol exclusions for hepatitis, HIV, tuberculosis, and active infection

> “Active Hepatitis B or Hepatitis C, history of positive HIV or positive HIV at screening, active tuberculosis or positive quantiferon test at screening.”
> “History of significant recurrent infections or any active infection at screening visit.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Autologous CD8+ T-cell product transfected with RNA, prepared from leukapheresis without withholding immunosuppression

> “Descartes-08 is an autologous CD8+ T-cell-only product that is transfected with RNA to express anti-BCMA targeting CAR protein over the course of a week.”
> “Eligible participants underwent leukapheresis to obtain peripheral blood mononuclear cells (PBMCs), from which Descartes-08 was prepared following Good Manufacturing Practices.”
> “Immunosuppression was not withheld before the collection of PBMCs.”
> “Aliquot(s) of cells were thawed at each infusion visit and infused by a peripheral intravenous line.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.5-2"></a>

#### Part 1 dose levels and Part 2 dose of 52.5 × 10⁶ CAR+ cells per kilogram

> “In Part-1 of the study (n=3), each participant received three ascending weekly doses of Descartes-08 as a 15–30-minute intravenous infusion of 3·5 × 10⁶ CAR+ cells/kg (Dose Level 1, DL1) 17·5 × 10⁶ CAR+ cells/kg (DL2), and 52·5 × 10⁶ CAR+ cells/kg (DL3) to determine the maximum tolerated dose (MTD) at the safety interim analysis, prior to proceeding to Part-2”
> “The allowed dose margin was ±45% for all dose levels.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

> “In Part‐2, up to 10 participants per arm with MGFA Class II–IV AChR‐Ab+, MuSK‐Ab+, or seronegative MG received the maximum administered dose of Descartes‐08 from Part‐1—which was 52.5 × 10⁶ viable CAR+ cells per kilogram—twice‐weekly for 3 weeks (Arm‐1), once‐weekly for 6 weeks (Arm‐2) or once‐monthly for 6 months (Arm‐3).”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.5-3"></a>

#### Care setting, post-infusion monitoring, premedication, and no lymphodepletion

> “Lymphodepletion chemotherapy was not used.”
> “For Part-1, participants were admitted to the hospital for their first infusion and observed as inpatient for three days and thereafter as outpatient daily until Day 7.”
> “Participants who received Descartes-08 as outpatients were observed for an hour post-infusion.”
> “Any participant with a fever of ≥38°C (≥100·4°F) within 7 days of infusion was admitted for 24-hour observation and evaluated for an infectious etiology with blood and urine cultures.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

> “Descartes‐08 was administered in an outpatient setting with 2 h of post‐infusion monitoring and without lymphodepletion chemotherapy (Figure 1A).”
> “In both parts, the participants received acetaminophen and diphenhydramine as premedication.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.5-4"></a>

#### Permitted and prohibited concomitant medications

> “Permitted MG concomitant medications were corticosteroids (≤40 mg prednisone/day equivalent), azathioprine, mycophenolate mofetil, pyridostigmine and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.”
> “No dosing change was allowed for concomitant MG-specific medications during the study, other than corticosteroids.”
> “The dose of corticosteroids was not allowed to be increased but it could be tapered at the site investigator’s discretion after Week 4.”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) were prohibited within 4 weeks of baseline and during the study.”
> “Other biologics, including rituximab and efgartigimod, were prohibited within 8 weeks of baseline and during the study.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.5-5"></a>

#### Manufacturing from all participants and cell doses delivered

> “We successfully produced Descartes-08 from all patients despite their use of immunosuppressants, with a potency comparable to a healthy volunteer (Figure s1).”
> “Three Part-1 participants received a median of 6·4 × 10⁹ CAR+ cells (range 6·3–7·2) over three infusions.”
> “In Part-2, 11 participants received a median of 17·3 × 10⁹ CAR+ cells (range 9·65–33·12) divided across a median of six infusions (range 3–6).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoints: tolerability in Part 1 and adverse events in Part 2

> “The primary objective of Part-1 was to determine tolerability.”
> “The primary endpoint of Part-2 was safety (frequency and severity of AEs) to final follow-up.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.6.1-2"></a>

##### Protocol primary endpoint: maximum tolerated dose

> “The primary endpoint is the Maximum Tolerated Dose (MTD) defined as the Dose Level at which no more than one patient has shown Dose-Limiting Toxicity (DLT) after Part 1 of the study is completed.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="topic-3.1.3.6.1-3"></a>

##### Rationale: toxicities of DNA CAR T-cells and the premise of RNA engineering

> “These aspects of DNA CAR T-cells limit their suitability for use beyond advanced cancers.”
> “To expand the range of conditions treatable with CAR T-cells beyond cancer, we engineered these cells with RNA (rCAR-T), rather than DNA, on the premise that the temporary, non-replicable influence of mRNA would confer predictable PK and consequently a more favorable safety profile.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.6.1-4"></a>

##### Secondary endpoints: MG-ADL, QMG, MGC, MG-QoL-15r, and MG PIS without a prespecified efficacy time point

> “Secondary endpoints were mean changes from baseline at each follow-up visit for up to 12 months (a primary efficacy time point was not pre-specified) in four validated scales of MG severity: Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative MG (QMG), MG Composite (MGC), and MG Quality of Life 15-revised (MG-QoL-15r) scores, as well as the MG Post-Intervention Status (MG PIS).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.6.1-5"></a>

##### Protocol responder endpoints: 2-point MG-ADL and QMG changes and 3-point MGC change

> “The proportion of patients achieving a ≥2-point change from Baseline up to Year 1 in the MG Activities of Daily Living (MG-ADL) score and Quantitative Myasthenia Gravis (QMG) score.”
> “The proportion of patients achieving a ≥3-point change from Baseline up to Year 1 in the MG Composite (MGC) score.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### Outcome scales and clinically meaningful change thresholds

> “MG-ADL is an 8-item, 24-point, patient-reported scale that assesses the impact of myasthenic symptoms on daily functioning.”
> “By convention, a 2-point change is considered clinically meaningful.”
> “QMG is a standardized, quantitative, 39-point scoring system consisting of 13 provider-assessed items, which include hand grip strength and forced vital capacity.”
> “MGC is a 10-item, 60-point weighted instrument composed of selected components of the MG-ADL and QMG scores.”
> “A 3-point change in QMG and MGC is considered clinically meaningful.”
> “Currently, there is no consensus as to what is considered a clinically meaningful change in MG-QoL-15r.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.6.1-7"></a>

##### Certified raters

> “The raters were certified in administering these scales.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment: up to 18 participants

> “Up to 18 adult patients with Myasthenia Gravis Foundation of America (MGFA) Grade III or IV (Part 1; Dose escalation) or Grade II-IV (Part 2; expansion phase) MG in whom immunosuppression therapy is clinically indicated in the judgement of the treating neurologist.”

Source: [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)

<a id="topic-3.1.3.7.1-2"></a>

##### No formal power analysis

> “As this was an early-phase open-label study with a dose-escalation regimen, no formal power analysis was performed.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.7.1-3"></a>

##### Enrolled participants: 3 in Part 1 and 11 in Part 2

> “14 participants were enrolled (n=3 in Part-1, n=11 in Part-2).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.7.1-4"></a>

##### Weekly-dosing arm analyzed through 12 months: 7 participants

> “All seven Arm‐2 participants completed 12 months of follow‐up, and the findings are reported here (Figure 1B).”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Safety analysis set: all 14 participants who received at least one dose

> “Fourteen patients, ages 18–83 years, meeting all eligibility criteria, received at least one dose of Descartes-08, and were included in the safety analysis (Table 1).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.7.2-2"></a>

##### Week 12 efficacy set: Part 2 Arm 1 and Arm 2 participants who completed 12-week follow-up

> “Includes data from Part-2 (Arm-1 and Arm-2) participants who completed 12-week follow-up.”
> “One Arm 1 participant was off-study prior to the first post-treatment assessment.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.7.2-3"></a>

##### Descriptive statistical methods

> “Baseline demographics and primary endpoints (type and frequency of AEs) were analyzed using descriptive statistics.”
> “Secondary and exploratory endpoints were expressed as mean change with a 95% Confidence Interval (CI), or proportion with Standard Error (SE).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

> “Numerical outcomes were expressed as mean change with a 95% confidence interval. We presented individual data points when n was 3 or fewer.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Screening, eligibility failures, and withdrawals

> “Sixteen patients were screened. Two did not qualify due to low baseline MG-ADL score (n=1) or lack of generalized disease (n=1) (Figure 1).”
> “Two of the 11 participants (18%) in Part-2 withdrew and did not complete all planned infusions: one due to urticaria (Arm 1, see below) and another for personal reasons unrelated to safety (Arm 3).”
> “The single Arm-3 participant withdrew from study after receiving 3 of 6 planned monthly infusions.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.1-2"></a>

##### Follow-up duration and Arm 1 discontinuations by Week 16

> “Median follow-up in Part-2 was 5 months (range: 3–9 months).”
> “By Week 16, all Arm-1 participants were off-study due to AE (n=1) or worsening symptoms requiring additional treatment (n=2); all 7 Arm-2 participants continue having MG scale scores below baseline during 6 months median follow-up (range 4–9 months).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.1-3"></a>

##### Arm 1 and Arm 3 discontinuation before full follow-up

> “As previously described, Arm‐1 and Arm‐3 participants discontinued study participation before the full protocol‐specified follow‐up period (Figure 1B) [8].”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Demographics and baseline characteristics by part and arm: all 14 participants

| Characteristic | Part 1 (n=3) | Part 2 Arm 1, twice weekly (n=3) | Part 2 Arm 2, weekly (n=7) | Part 2 Arm 3, monthly (n=1) | All participants (n=14) |
| --- | --- | --- | --- | --- | --- |
| Age, mean (SD), years | “57 (16)” | “43 (26)” | “52 (16·8)” | “70” | “52 (18)” |
| Female sex, no. (%) | “2/3” | “2/3” | “5/7” | “1/1” | “10 (71%)” |
| MGFA class II at screening | “0” | “0” | “3/7” | “0” | “3 (21%)” |
| MGFA class III at screening | “3/3” | “2/3” | “4/7” | “1/1” | “10 (72%)” |
| MGFA class IV at screening | “0” | “1/3” | “0” | “0” | “1 (7%)” |
| Duration of disease, median (range), years | “13 (5–25)” | “14 (4–15)” | “16 (3–27)” | “26” | “14 (3–27)” |
| Anti-AChR antibody | “3/3” | “3/3” | “4/7” | “1/1” | “11 (79%)” |
| Anti-MuSK antibody | “0” | “0” | “2/7” | “0” | “2 (14%)” |
| Seronegative | “0” | “0” | “1/7” | “0” | “1 (7%)” |
| Baseline QMG, mean (SD) | “14·3 (3·5)” | “17·3 (1·5)” | “15·9 (4·5)” | “8” | “15·3 (4·1)” |
| Baseline MG-ADL, mean (SD) | “8·7 (3·8)” | “10·7 (3·5)” | “10·7 (3)” | “6” | “10 (3·2)” |
| Baseline MGC, mean (SD) | “19·3 (6·7)” | “24·7 (4·7)” | “23 (5·2)” | “13” | “21·9 (5·7)” |
| Baseline MG-QoL-15r, mean (SD) | “23·3 (3·1)” | “19·1 (9)” | “19·7 (5·1)” | “12” | “19·9 (5·8)” |
| Prior eculizumab | “0” | “0” | “2/7” | “0” | “2 (14%)” |
| Prior rituximab | “0” | “0” | “2/7” | “0” | “2 (14%)” |
| Prior IVIg | “1/3” | “3/3” | “7/7” | “1/1” | “12 (86%)” |
| Prior plasma exchange | “0” | “3/3” | “5/7” | “0” | “5 (36%)” |
| Prior thymectomy | “1/3” | “2/3” | “3/7” | “0” | “6 (43%)” |
| Prior MG crisis requiring intubation | “1/3” | “1/3” | “2/7” | “0” | “4 (29%)” |
| Pyridostigmine at baseline | “2/3” | “3/3” | “6/7” | “0” | “11 (79%)” |
| Prednisone at baseline | “3/3” | “2/3” | “5/7” | “0” | “10 (71%)” |

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.2-2"></a>

##### Disease severity at screening, antibody status, and concomitant therapy: all 14 participants

> “Most participants (10 of 14, 71%) had MGFA class III disease, with a median MG-ADL score of 11 (range 6–15), median QMG score of 16 (range 8–24), and median MGC score of 23 (range 12–30) at screening.”
> “Eleven patients had a history of anti-AChR antibodies; two had anti-MuSK antibodies; and one was seronegative for AChR, MuSK and LRP4 antibodies.”
> “Most participants (11 of 14, 79%) continued pyridostigmine, and 10 of 14 (71%) received corticosteroids throughout the study (mean dose 19.5 mg/day, range 5–40 mg/day).”
> “All participants had previously received at least one of the following: IVIg, corticosteroids, non-steroidal immune suppressants, or PLEX (Table 1).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.2-3"></a>

##### Weekly-dosing arm characteristics: 7 participants

> “Seven patients were enrolled in Arm‐2, of whom 5 were females, 4 (57%) were AChR‐Ab+, 3 (43%) had previously undergone thymectomy, and all had received previous immunosuppressive treatments and IVIG.”
> “Most participants continued the use of pyridostigmine and corticosteroids throughout the study.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Part 1: variable reductions in severity scores and one prednisone taper

> “Part-1 participants showed variable reductions in mean MG-ADL, QMG, MGC, and QoL-15r scores at Weeks 3–24 (Figure s2).”
> “One participant tapered their dose of prednisone from 40 mg daily before treatment to 25 mg daily at final (12-month) follow-up.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.3-2"></a>

##### Part 2 Arms 1 and 2: mean changes at Week 12 and onset of response

> “Part-2 participants enrolled in Arms 1 and 2 experienced decreases in all disease severity scores by Week 5; in Arm-2, these reductions deepened further by Week 8 and subsequently plateaued (Figure 2).”
> “Mean [95% CI] improvements at Week 12 — the last time point when data for all Arm-1 and Arm-2 participants were available — were −5·9 [−9, −2·8] (MG-ADL), −7 [−11, −3] (QMG), −14 [−19, −9] (MGC), and −9 [−15, −3] (MG-QoL-15r) (Table 3).”
> “Repeatable numerical improvement in multiple MG scales pointing towards clinical symptom improvement was observed in all 9 participants who reached Week 8, and 8 of 9 (89%) at Week 12.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.3-3"></a>

##### Measures of disease severity at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up

| Measure at Week 12 | All, n=9 (mean change, 95% CI) | Arm 1, n=2 (individual values) | Arm 2, n=7 (mean change, 95% CI) | AChR+, n=6 (mean change, 95% CI) | MuSK+, n=2 (individual values) | Seronegative, n=1 |
| --- | --- | --- | --- | --- | --- | --- |
| MG-ADL | “−5·9 [−9, −2·8]” | “−6, −8” | “−6 [−15, +3]” | “−6 [−11, −1]” | “−3, −4” | “−8” |
| QMG | “−7 [−11, −3]” | “−5, −3” | “−8 [−20, +4]” | “−5 [−10, 0]” | “−9, −5” | “−17” |
| MGC | “−14 [−19, −9]” | “−7, −11” | “−15 [−29, −1]” | “−14 [−21, −7]” | “−14, −7” | “−22” |
| MG-ADL decrease ≥2, No. | “8/9” | “2/2” | “6/7” | “5/6” | “2/2” | “1/1” |
| MGC decrease ≥3, No. | “9/9” | “2/2” | “7/7” | “6/6” | “2/2” | “1/1” |
| QMG decrease ≥3, No. | “8/9” | “2/2” | “6/7” | “5/6” | “2/2” | “1/1” |
| MG-ADL decrease ≥6, No. (post hoc) | “5/9” | “2/2” | “3/7” | “4/6” | “0/2” | “1/1” |

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.3-4"></a>

##### Responder definitions: prespecified 2-point and reported 3-point QMG thresholds, and post hoc MG-ADL depth of response

> “All participants who had the pre-specified ≥2-point improvement in QMG also had a ≥3-point improvement.”
> “Post-hoc analysis of depth of response.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.3-5"></a>

##### Minimal symptom expression, IVIg independence, and concomitant medications: Part 2 Arm 2

> “Three Arm-2 participants (43%) achieved minimal symptom expression (MSE, defined as MG-ADL of 0 or 1)”
> “in at least one post-treatment follow-up; two of the three have maintained MSE through the most recent (6-month) follow-up.”
> “Two other Arm-2 participants who, before enrollment, required weekly or biweekly IVIg infusions have not needed further IVIg during follow-ups at 4 and 6 months, respectively.”
> “There were no changes in concomitant MG-specific medications reported in any Part-2 participants during the study period.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.3-6"></a>

##### Weekly-dosing arm at Month 3: clinically meaningful improvement in all 7 participants

> “All seven participants who received six weekly infusions of Descartes‐08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15‐revised) at Month 3 without significant toxicity.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-7"></a>

##### Weekly-dosing arm at Month 9: mean changes in MG-ADL, MGC, QMG, and QoL-15r, 7 participants

> “At Month 9, approximately 7 months after the last infusion and without new or increased MG‐directed drugs, all participants continued to experience substantial clinical responses as measured by MG‐ADL (mean change −6.3 [95% CI −3.5 to −9.1], Figure 2A), MGC (−16.6 [−13.4 to −19.5], Figure 2B), QMG (−8.4 [−5.2 to −11.6], Figure 2C), and QoL‐15r (−12 [−8 to −16], Figure 2D).”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-8"></a>

##### Weekly-dosing arm at Month 12: maintained response in 5 of 7 participants

> “At Month 12, 5 of the 7 participants maintained clinically meaningful improvement, including one with MSE, with mean change in MG‐ADL −4.6 [95% CI −8.8 to −0.4], MGC −11.3 [−18.0 to −4.6], QMG −6.3 [−10.5 to −2.0] and QoL‐15r −7.7 [−15.6 to −8.4].”
> “In this 12‐month follow‐up, we observed durable responses sustained up to 12 months in 5 of the 7 (71%) participants who received six once‐weekly doses.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-9"></a>

##### Weekly-dosing arm: prednisone dose and IVIg use through Month 12

> “Five of the 7 participants received prednisone at baseline, with a median daily dose of 17.5 mg. By Month 12, the median dose decreased to 5 mg daily.”
> “Neither of the two participants who were receiving IVIG once and twice monthly at baseline required IVIG during the 12 months of follow‐up.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-10"></a>

##### Weekly-dosing arm: anti-AChR antibody reductions through Month 12

> “Three of the four participants with reported anti‐AChR antibody exhibited detectable levels at baseline, and all three showed reductions in antibody levels by Month 6 (−17%, −44%, and −65%).”
> “These reductions continued at Month 9 (−35%, −100% [undetectable], and −70%), and persisted at Month 12 (−33%, −44% and −65% reductions, Figure 5A).”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-11"></a>

##### Relapse at Month 12 and Month 18 and retreatment in the weekly-dosing arm

> “Two participants with anti‐AChR antibody‐positive MG experienced worsening disease at Month 12 and became eligible for retreatment (Table S1); both opted for retreatment.”
> “At Month 18 after initial treatment, a third participant, with triple‐seronegative MG, experienced MG worsening and opted for retreatment.”
> “Retreatment consisted of repeat apheresis followed by six once‐weekly infusions of target 52.5 × 10⁶ viable CAR+ cells per kg in an outpatient setting and without lymphodepletion.”
> “All three participants experienced a rapid improvement in MG‐specific clinical scores; two achieved MSE by Week 8, which was maintained through 12 months of post retreatment follow‐up (Figure 3).”
> “The third participant experienced similar improvement in MG severity scores to their initial treatment.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.3-12"></a>

##### Company-reported retreatment analysis: third phase 2a retreated participant at Month 12

> “The third retreated participant’s responses deepened from a 4-point MG-ADL reduction at Month 2 to a 9-point improvement in MG-ADL at Month 12 following retreatment.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-3.1.3.8.3-13"></a>

##### Company-reported retreatment analysis: pooled phase 2a and 2b case series design, September 2026

> “Retreatment case series: In a pooled case series of 5 participants with gMG from the Phase 2a and Phase 2b MG-001 studies who responded to an initial 6-week course of Descartes-08 and experienced recurrence of symptoms (MG-ADL ≥6), retreatment with Descartes-08 demonstrated improvements in MGC and MG-ADL scores, with benefit sustained through 12 months and no new safety signals observed.”
> “Retreatment consisted of 6 once-weekly Descartes-08 infusions”
> “All participants had 12-month follow-ups for both initial treatment and retreatment”

Source: [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

<a id="topic-3.1.3.8.3-14"></a>

##### Company-reported retreatment analysis: baseline characteristics of the pooled case series, 5 participants

| Characteristic | Participants (n=5) |
| --- | --- |
| Age, mean (SD) | “58 (12) years” |
| Age range | “49–79” |
| Women, n (%) | “4 (80%)” |
| AChR+ gMG, n (%) | “4 (80%)” |
| MG-ADL at baseline before initial treatment, mean (SD) | “9.2 (3.1)” |
| MG-ADL at baseline before retreatment, mean (SD) | “9.6 (3.4)” |
| Median interval between end of initial treatment course and first retreatment infusion | “16.6 months”; “(range 11.7–22.6)” |

Source: [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

> “Patients had a mean disease duration of 13 years with extensive treatment histories.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="topic-3.1.3.8.3-15"></a>

##### Company-reported retreatment analysis: MG-ADL and MGC changes at Month 12 after retreatment, 5 participants

> “Retreated patients observed an average MG-ADL reduction of 6.6 (±4.2) points from baseline at Month 12.”
> “Retreated patients observed an average MGC reduction of 15 (±6.2) points from baseline at Month 12.”
> “All retreated patients experienced a clinically meaningful reduction across MGC (≥3-point reduction) and MG-ADL scores (≥2-point reduction), and four patients maintained the clinically meaningful MG-ADL reduction through Month 12 following retreatment.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

> “The reduction in mean MG-ADL score from baseline following retreatment was consistent with, and potentially greater than, that observed following initial treatment”

Source: [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### MG-QoL-15r change at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up

| Measure at Week 12 | All, n=9 (mean change, 95% CI) | Arm 1, n=2 (individual values) | Arm 2, n=7 (mean change, 95% CI) | AChR+, n=6 (mean change, 95% CI) | MuSK+, n=2 (individual values) | Seronegative, n=1 |
| --- | --- | --- | --- | --- | --- | --- |
| MG-QoL-15r | “−9 [−15, −3]” | “−8, +4” | “−11 [−23, +1]” | “−8 [−17, +1]” | “−10, −6” | “−14” |

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### No dose-limiting toxicity, cytokine release syndrome, or neurotoxicity

> “There was no dose-limiting toxicity, cytokine release syndrome (CRS), or neurotoxicity.”
> “There were no dose-limiting toxicities (DLTs), treatment-related SAEs, or Grade ≥3 AEs in Part-1 (Table 2), making DL3 the MTD.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-2"></a>

##### Serious adverse events: influenza before treatment, grade 3 urticaria, and myocardial infarction

> “One SAE unrelated to Descartes-08 (Grade 2 influenza requiring hospitalization, which occurred after apheresis but before treatment initiation) was reported in Part-1.”
> “Two SAEs were reported in Part-2. The first was Grade 3 urticaria 24 hours after the third infusion in a participant with a prior history of drug-induced urticaria; skin biopsy was consistent with a typical drug reaction, and serum tryptase and cytokine levels were normal (Table s3).”
> “The urticaria was deemed possibly related to Descartes-08 and resolved completely after the administration of intravenous steroids.”
> “The second SAE was a non-ST segment elevation myocardial infarction occurring 72 hours after the sixth infusion in an 83-year-old man with a history of hypertension and hyperlipidemia.”
> “The investigator deemed the event unrelated to Descartes-08.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-3"></a>

##### Adverse events related to Descartes-08 by part and arm: all 14 participants

| Term | Grade | Part 1 (n=3) | Part 2, all arms (n=11) | Part 2 Arm 1 (n=3) | Part 2 Arm 2 (n=7) | Part 2 Arm 3 (n=1) |
| --- | --- | --- | --- | --- | --- | --- |
| Hand numbness | “2” | “1/3” | Not reported | Not reported | Not reported | Not reported |
| Headache | “1” | “1/3” | “5 (45%)” | “1/3” | “3/7” | “1/1” |
| Muscle soreness | “1” | “1/3” | “1 (9%)” | Not reported | “1/7” | Not reported |
| Nausea | “1” | “1/3” | “4 (36%)” | “2/3” | “2/7” | Not reported |
| Rash | “3” | Not reported | “1 (9%)” | “1/3” | Not reported | Not reported |
| Itchy throat | “1” | Not reported | “2 (18%)” | Not reported | “1/7” | “1/1” |
| Vomiting | “1” | Not reported | “3 (27%)” | “2/3” | “1/7” | Not reported |
| Weakness | “1” | Not reported | “2 (18%)” | “2/3” | Not reported | Not reported |
| Line infiltration | “1” | Not reported | “1 (9%)” | “1/3” | Not reported | Not reported |
| Fever | “1” | Not reported | “4 (36%)” | “1/3” | “3/7” | Not reported |
| Shortness of breath | “1” | Not reported | “2 (18%)” | “1/3” | “1/7” | Not reported |
| Chills | “1” | Not reported | “2 (18%)” | “1/3” | “1/7” | Not reported |
| Diarrhea | “1” | Not reported | “1 (9%)” | “1/3” | “1/7” | Not reported |
| Gum inflammation | “1” | Not reported | “1 (9%)” | Not reported | “1/7” | Not reported |
| Teeth sensitivity | “1” | Not reported | “1 (9%)” | Not reported | “1/7” | Not reported |
| Night sweats | “1” | Not reported | “1 (9%)” | Not reported | “1/7” | Not reported |
| Restless leg | “1” | Not reported | “1 (9%)” | Not reported | “1/7” | Not reported |
| Lightheadedness | “1” | Not reported | “1 (9%)” | Not reported | “1/7” | Not reported |

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-4"></a>

##### Adverse event counting rules and grade distribution

> “Each AE was counted once per patient, at the highest grade reported.”
> “Relatedness includes possibly, probably, or likely”
> “There were no Grade ≥3 events reported in Part-1, and no Grade 2 or Grade 4 events reported in Part-2.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-5"></a>

##### Infusion-associated fever without cytokine release syndrome markers

> “Headache, fever, and nausea were the most common treatment-related AEs in Part-2, reported in 5 (45%), 4 (36%), and 4 (36%) of 14 patients, respectively.”
> “All fevers occurred 4–6 hours after infusion and resolved within 24 hours.”
> “None of these patients had positive urine or blood cultures or received empiric antibiotics.”
> “There were no episodes of hypotension, hypoxia, or requirement for the use of tocilizumab or steroids for treatment of or prevention of CRS.”
> “Fevers were not associated with elevated markers of CRS (interleukin-6, interleukin-2, and tumor necrosis factor-α).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-6"></a>

##### Humoral immunity: immunoglobulins and vaccine titers through Week 12

> “No patient showed evidence of functional immunosuppression (i.e. new hypogammaglobulinemia or disappearance of previously therapeutic levels of vaccine titers) or opportunistic infection.”
> “Anti-tetanus IgG antibodies were detected in all 9 participants (median [range] at Day 1 93·7 [8·5–850·9] Units/mL) and did not change (Figure 3G).”
> “The median total IgG among the 9 participants was 1325 [range 383–2862] mg/dL and decreased up to 18% [95%CI −6–42%] by Week 12, while IgA and IgM levels remained unchanged during treatment (Figures 3H–I).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.8.5-7"></a>

##### Weekly-dosing arm through Month 12: no new product-related adverse events

> “Descartes‐08 maintained a favorable safety profile, with no new product‐related adverse events reported during the 12‐month follow‐up period.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.5-8"></a>

##### Weekly-dosing arm through Month 12: meningococcal antibody titers and total immunoglobulin

> “Five of the seven participants had circulating anti‐meningococcal antibodies at baseline, all from prior vaccination.”
> “There was a small but detectable decrease in these antibodies at Month 3, which deepened by Month 9 (−48% [−25% to −75%]) and stabilized by Month 12 to lower but still protective levels (−48% [−35% to −69%], Figure 5B), following a similar pattern to the anti‐AChR antibody reduction.”
> “In contrast, there was no appreciable decrease in total immunoglobulin (Figure 5C), other vaccine‐associated antibodies (Figure S1), or soluble BCMA (sBCMA, Figure 6A), indicating that the targeting of BCMA‐positive plasma cells was not indiscriminate.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.5-9"></a>

##### Cumulative open-label safety: anaphylaxis, CRS, ICANS, and hematologic toxicity across 14 participants and 88 infusions

> “In contrast, there were no cases of anaphylaxis reported across 14 patients treated and 88 administered infusions with Descartes‐08 in MG, including in 3 participants who received a total of 12 infusions each.”
> “No cases of CRS or ICANS were observed among the 14 open‐label MG‐001 participants dosed with Descartes‐08, and no reported use of tocilizumab or corticosteroid.”
> “As there is no lymphodepletion chemotherapy required, there were no associated hematologic toxicities in any of the 14 patients with MG who received Descartes‐08.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.5-10"></a>

##### Safety after retreatment in the weekly-dosing arm, 3 participants

> “The safety profile was unchanged compared to the initial treatment.”
> “Notably, the three participants reported fewer adverse events after retreatment while experiencing the same or better numeric improvement across MG severity scales all the way to MSE.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-3.1.3.8.5-11"></a>

##### Company-reported retreatment analysis: safety events after initial treatment and retreatment, 5 participants

| Safety event | Initial treatment (n=5) | Retreatment (n=5) |
| --- | --- | --- |
| Serious adverse events | “1” | “0” |
| Infusion-related reaction | “16/30 infusions” | “17/30 infusions” |
| Infusion-related reaction, grade 1 | “10” | “12” |
| Infusion-related reaction, grade 2 | “6” | “5” |
| Tachycardia | “1” | “5” |
| CRS | “0” | “0” |
| ICANS | “0” | “0” |
| Cytopenias | “0” | “0” |
| Hypogammaglobulinemia | “0” | “0” |

Source: [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

> “Participant had an infected port not related to Descartes-08”
> “All occurred in the same participant with 4 of 5 events ocurring in combination with infusion reaction”

Source: [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

<a id="topic-3.1.3.8.5-12"></a>

##### Company-reported retreatment analysis: tolerability through Month 12 after retreatment

> “Descartes-08 was observed to be generally well-tolerated through Month 12 following retreatment, and adverse events were transient and mild. No serious adverse events were reported during retreatment. Notably, there were no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, or hypogammaglobulinemia.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Design: the study was open label, nonrandomized, and without a control arm, and the authors state that a placebo effect cannot be excluded and that comparison with historical controls is not conclusive. Part 2 participants were assigned to dosing arms at the investigator's discretion, taking participant preference into account.
- Sample size: 14 participants were enrolled (3 in Part 1 and 11 in Part 2), and no formal power analysis was performed. The week 12 efficacy analysis included 9 Part 2 participants, and only 2 participants had MuSK antibody-positive disease and 1 had seronegative disease. Three participants had MGFA class II disease, which the authors note may improve to minimum symptom expression with conventional treatment.
- Endpoints: efficacy measures were secondary endpoints with no prespecified primary efficacy time point, and the analysis of MG-ADL decreases of 6 points or more was post hoc. Corticosteroid tapering was permitted after week 4 at the investigator's discretion, and the authors state that an effect of the unchanged maintenance dose cannot be excluded in the absence of a control arm.
- Follow-up and attrition: median follow-up in Part 2 was 5 months (range 3 to 9) in the initial report. By week 16 all twice-weekly arm participants were off study (adverse event, n = 1; worsening symptoms, n = 2), and the single monthly-arm participant withdrew after 3 of 6 infusions. The 12-month analysis is limited to the 7 weekly-arm participants, of whom 5 maintained clinically meaningful improvement at month 12.
- Retreatment and biomarkers: the authors state that more experience with initial treatment and retreatment is needed, that allergic reactions including anaphylaxis cannot be excluded, and that circulating antibody titers may not reflect tissue concentrations. The pooled retreatment case series of 5 participants is company-reported.
- Reporting: the sponsor took part in the design, data collection, interpretation, analysis, manuscript writing, and decision to submit. The text gives the most common treatment-related adverse events in Part 2 as 5 (45%), 4 (36%), and 4 (36%) “of 14 patients”, while the table reports these counts for Part 2 (n = 11). The month-12 MG-QoL-15r change is printed as “−7.7 [−15.6 to −8.4]”, an interval that does not contain its point estimate.

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/); [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/); [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)

<a id="topic-3.1.3.9-2"></a>

#### Small, open-label, uncontrolled design: author-stated limitations

> “Our study has the inherent limitations of a small, open-label trial, including the potential for placebo effect, and limited ability to draw inferences from secondary, exploratory and subgroup analyses.”
> “Second, three participants had MGFA Class II MG, which may improve to MSE even with conventional treatments.”
> “Although it is unlikely that the observed magnitude of symptom improvement could be attributed solely to this unchanged maintenance dose, or to the placebo effect, in the absence of a control arm such a possibility cannot be excluded.”
> “Third, there were only 2 participants with MuSK, and only 1 with seronegative MG.”
> “Comparison to historical controls is not conclusive, and therefore a more complete assessment of efficacy is underway in a randomized, placebo-controlled study using six weekly doses of Descartes-08 for MG (NCT04146051).”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.9-3"></a>

#### Sponsor role in design, analysis, and reporting

> “The Sponsor (Cartesian Therapeutics) played a part in the design of the study, data collection, interpretation, analysis, writing of the manuscript, and the decision to submit.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-3.1.3.9-4"></a>

#### Limited retreatment experience, allergic reactions, and antibody titers as biomarkers

> “More experience with initial treatment and retreatment would be needed to confirm this hypothesis.”
> “As with any form of biologic therapy, allergic reactions, including anaphylaxis, cannot be excluded.”
> “However, the onset of clinical improvement was more rapid than the autoantibody reduction, and circulating antibody titers may not accurately reflect their concentration at the tissue level.”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
